Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of giving consent.
• People who are fluent English speakers, with reading and speaking skills assessed by the site investigator as being at a native speaker level.
• People with a general health and activity level rated as reasonably functional, assessed within 14 days before joining (confirm with trial site for specific rating scale used).
• People who have been diagnosed with Stage IV non-small cell lung cancer (a specific type and stage of lung cancer), confirmed through laboratory tissue or cell testing.
• People who have at least one cancer lesion in the brain, confirmed by MRI scan.
• People whose cancer has tested positive for a specific genetic change called an ALK rearrangement, confirmed through standard local testing.
• People who have brain cancer lesions that are either causing no symptoms or only mild symptoms, and for whom surgery on the brain is not planned within 28 days of starting the study. People whose neurological symptoms are managed with steroid or anti-seizure medications may also be eligible.
• People who have a specific type of cancer spread involving the lining of the brain and spinal cord (leptomeningeal disease) but have no symptoms from it may be eligible, provided all other criteria are also met.
• People who are planning to be treated with a drug called alectinib. This drug may have already been started up to 8 weeks before joining the trial.
• People who have previously received certain cancer treatments (such as chemotherapy, radiation, immunotherapy, or a combination) for non-metastatic disease, as long as at least 3 months have passed since the last treatment cycle before joining the trial.
• People who have had a consultation with a radiation specialist who has reviewed and approved the radiation treatment plan for the study.
• People whose blood test results show that major organs such as the liver and kidneys are working adequately, tested within 14 days before joining.
• Women who could potentially become pregnant must have a negative blood pregnancy test within 14 days before joining.
• Women who could potentially become pregnant, and men, must be willing to either avoid heterosexual intercourse or use effective contraception throughout the study, as outlined in the study protocol.
• People living with HIV who are on effective treatment and have had an undetectable level of the virus in their blood within the 6 months before joining.
• People with a long-term hepatitis B infection must have an undetectable viral level while on appropriate treatment. People with a history of hepatitis C must have completed treatment and been cured, or if currently being treated for hepatitis C, must have an undetectable viral level.
• People who are able to understand and follow the study procedures for the full length of the study, as determined by the enrolling doctor.

Who may not be able to join:

• People who currently have an active infection that requires treatment with systemic (whole-body) medication.
• People who have a condition that affects the body's ability to absorb medication taken by mouth.
• People who are currently pregnant or breastfeeding.
• People who have had, or currently have, another type of cancer whose history or treatment could affect the safety or effectiveness of this trial, as determined by the treating doctor.
• People who have taken part in another clinical trial involving an experimental drug within 28 days before joining.
• People who currently have an acute (sudden or active) form of hepatitis, including viral, autoimmune, alcohol-related, or other types.

Important: Always verify eligibility with the trial site directly before applying.